Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct 1;15(19):5950-5.
doi: 10.1158/1078-0432.CCR-08-3205. Epub 2009 Sep 29.

A comparison of phase II study strategies

Sally Hunsberger  1 , Yingdong Zhao, Richard Simon
Affiliations
Review

A comparison of phase II study strategies

Sally Hunsberger et al. Clin Cancer Res. .

Abstract

The traditional oncology drug development paradigm of single arm phase II studies followed by a randomized phase III study has limitations for modern oncology drug development. Interpretation of single arm phase II study results is difficult when a new drug is used in combination with other agents or when progression-free survival is used as the endpoint rather than tumor shrinkage. Randomized phase II studies are more informative for these objectives but increase both the number of patients and time required to determine the value of a new experimental agent. In this article, we compare different phase II study strategies to determine the most efficient drug development path in terms of number of patients and length of time to conclusion of drug efficacy on overall survival.

PubMed Disclaimer

References

    1. Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol. 1993;11:794–801. - PubMed
    1. Green S, Benedetti J, Crowley J. Clinical trials in oncology. Chapman & Hall; 1997.
    1. Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol. 1988;41:1209–13. - PubMed
    1. Makuch RW, Simon RM. Sample size considerations for nonrandomized comparative studies. Journal of Chronic Disease. 1980;33:175–181. - PubMed
    1. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16. - PubMed

MeSH terms